Numerof & Associates December 9, 2025
This year brought major shifts in the pharmaceutical landscape as the Trump Administration negotiated directly with manufacturers, used tariff threats to force lower prices and reshoring, issued new executive orders on affordability and introduced a national direct-to-consumer pricing model.
...






